Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LGL13K
- Development stage
- Unknown
- Lead developer
- Gavia BIO
- Modality
- Peptides
- Administration
- Topical
01
Overview
LGL13K is a 13-amino-acid cationic antimicrobial peptide (AMP) derived from the salivary protein BPI fold-containing family A member 2 (BPIFA2, formerly parotid secretory protein). It is the L-form stereoisomer of DGL13K (Minneganan). LGL13K exhibits bactericidal activity primarily against Gram-negative bacteria, such as *Pseudomonas aeruginosa* and *Escherichia coli*, as well as their biofilms. It acts by binding to lipopolysaccharide (LPS) and disrupting the bacterial cell membrane. However, unlike its protease-resistant D-enantiomer DGL13K, LGL13K is susceptible to degradation by bacterial proteases and is less effective against Gram-positive bacteria. It is primarily utilized as a research-stage comparator in studies evaluating antimicrobial peptide efficacy and resistance mechanisms.
- Other names
- L-GL13KL-GL-13KL-GL 13K
Beyond the preview
Go deeper on LGL13K.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LGL13K.